

# Expert Opinion

1. Introduction
2. Background
3. Conclusion
4. Expert opinion

## VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration

James A Dixon, Scott CN Oliver<sup>†</sup>, Jeffrey L Olson & Naresh Mandava  
*University of Colorado Denver, Rocky Mountain Lions Eye Institute, Department of Ophthalmology,  
 1675 North Aurora Court, PO Box 6510, Mail Stop F-731, Aurora, CO 80045-2500, USA*

**Background:** Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry form, neovascular AMD accounts for the vast majority of patients who develop legal blindness. Until recently, few treatment options existed for treatment of neovascular AMD. The advent of anti-VEGF therapy has significantly improved the safe and effective treatment of neovascular AMD. In addition to two anti-VEGF drugs currently in widespread use, ranibizumab and bevacizumab, a number of medications that interrupt angiogenesis are currently under investigation. One promising new drug is aflibercept (VEGF Trap-Eye), a fusion protein that blocks all isoforms of VEGF-A and placental growth factors-1 and -2. **Objective:** To review the current literature and clinical trial data regarding VEGF Trap-Eye for the treatment of neovascular AMD. **Methods:** Literature review. **Results/conclusion:** VEGF Trap-Eye is a novel anti-VEGF therapy, with Phase I and II trial data indicating safety, tolerability and efficacy for the treatment of neovascular AMD. Two Phase III clinical trials (VIEW-1 and VIEW-2) comparing VEGF Trap-Eye to ranibizumab are currently continuing and will provide vital insight into the clinical applicability of this drug.

**Keywords:** aflibercept, AMD, angiogenesis, neovascularization, VEGF, VEGF inhibition, VEGF Trap

*Expert Opin. Investig. Drugs (2009) 18(10):1573-1580*

### 1. Introduction

Age-related macular degeneration (AMD) affects > 1.75 million individuals in the US and it is estimated that by 2020 this number will increase to almost 3 million [1]. Worldwide, AMD is estimated to affect 14 million people [2]. While the vast majority of patients suffering from AMD have the dry form, ~ 80 – 90% of patients who develop severe vision loss have the neovascular or 'wet' form of the disease [3]. Until recently, healthcare professionals had few options when it came to treating neovascular AMD. For many years, subfoveal choroidal neovascularization (CNV) was treated with argon laser therapy according to guidelines from the Macular Photocoagulation Study [4-12]. This treatment, in the setting of subfoveal disease, was unsatisfactory for a number of reasons, including the limited benefits in visual stabilization and the high risk of inducing central vision deficits [13]. Treatment outcomes improved with the introduction of photodynamic therapy (PDT) which utilized a photosensitizing dye (verteporfin) to selectively target CNV. While more efficacious than previous treatments, patients receiving PDT failed to recover vision and continued to experience a decline in visual acuity [14] and the treatment was of questionable cost effectiveness [15].

The more recent development of agents that inhibit VEGF has largely supplanted these previous treatments. The pathogenesis of CNV in the setting of

**informa**  
healthcare

AMD is complex; however, there is overwhelming evidence that VEGF is a predominant mediator in its genesis. VEGF receptors are expressed by a number of important cell types in the eye, including vascular endothelial cells, choroidal fibroblasts, retinal pigment epithelial cells and inflammatory cells attracted by hypoxia [16-19]. Higher levels of VEGF expression have been demonstrated in animal models [20,21] and human studies of eyes with AMD [17,22-24] and antagonism of VEGF in both settings have definitively demonstrated inhibition of neovascularization and vascular permeability. VEGF-A is the predominant member of the VEGF family targeted by drugs currently in widespread use; however, the group is also comprised of VEGF-B, VEGF-C, VEGF-D and placental growth factors-1 and -2.

Systemic administration of bevacizumab is effective against neovascular AMD; however, systemic complications limit its use [25]. Accordingly, all anti-VEGF agents for neovascular AMD are administered only by intravitreal injection. The two largest studies examining anti-VEGF therapy, the MARINA [26] and the ANCHOR [27,28] trials, were randomized, controlled, double-masked Phase III clinical trials that together evaluated monthly ranibizumab for the treatment of all types of neovascular AMD. In both trials, 94% of patients with neovascular AMD lost fewer than 15 letters of visual acuity at 12 and 24 months when treated with ranibizumab. Surprisingly, as many as 40% of patients in the two trials improved by > 15 letters from baseline at 2 years. Ranibizumab received the FDA approval for all types of neovascular AMD in 2006. Based on the results of these two landmark studies, anti-VEGF therapies for neovascular AMD have largely replaced previous treatment modalities.

## 2. Background

### 2.1 Overview of the market (unmet needs, competitor compounds/in clinical development)

By far the most commonly used anti-VEGF drugs currently in use for neovascular AMD are ranibizumab and bevacizumab. Pegaptanib was the first anti-VEGF drug approved by the FDA for the treatment of AMD; however, it proved less efficacious than current treatments [13] (possibly due to its selective binding of VEGF-165) and is no longer widely used in most countries. Ranibizumab is the only drug in widespread use currently approved by the FDA for treatment of neovascular AMD and is by far the most extensively studied [26,27,29,30]. It is a recombinant monoclonal antibody fragment with a high binding affinity for all isotypes of VEGF-A. Bevacizumab, currently being used off-label for the treatment of AMD in the US, is a humanized whole antibody to VEGF-A used in oncology regimens that also binds all isotypes of VEGF-A. Although ranibizumab has been shown to have a higher affinity for VEGF-A, it is not clear if ranibizumab has superior efficacy to bevacizumab. Retrospective and small randomized studies have suggested similar efficacy profiles [31,32]. The Comparisons of Age-Related

Macular Degeneration Treatment Trial (CATT) is a 2-year, multi-centered, randomized clinical trial comparing ranibizumab and bevacizumab for neovascular AMD. Enrollment began in February 2008. Despite the off-label status of bevacizumab, it continues to be a popular treatment choice in the US because of the significantly reduced price of treatment (\$ 50 – 100 for bevacizumab versus \$ 2000 for ranibizumab (2008 pricing)).

As previously mentioned, the MARINA [26] and the ANCHOR [27,28] trials examined the efficacy of ranibizumab when administered monthly. The time and financial burden of monthly injections has led to the initiation of studies to examine the efficacy of alternative dosing schedules. In the PIER study [30], patients initially received monthly injections of ranibizumab for 3 months followed by quarterly injections. Although patient visual acuities actually improved at 3 months, during the quarterly dosing segment visual acuity returned to baseline. The PrONTO study [29] looked at as needed (p.r.n.) dosing of ranibizumab after three consecutive monthly doses. The need for further injections was made on the basis of recurrent CNV as evidenced by worsening vision, retinal thickening on ocular coherence tomography (OCT) or abnormalities on fluorescein angiogram (FA). At 2 years of follow up, 78% of patients had maintained vision and vision had improved by > 3 lines in 43% of patients with an average of five injections a year. These later studies seem to indicate that quarterly dosing is associated with poorer outcomes but it may be possible to extend the time between injections if the patient is frequently monitored. However, even with the p.r.n. dosing utilized in the PrONTO study, patients are still required to make monthly visits to the office with frequent and expensive testing.

The development of new drugs for neovascular AMD has thus focused on both improving efficacy and extending duration of action. Most new compounds in development are targeted toward inhibition of various steps in the VEGF signaling pathway. There are a number of drugs in development that inhibit the downstream tyrosine kinase cascade activated by the binding of VEGF with its receptor (VEGFR). Vatalanib is an oral formulation that binds to all three VEGFRs and has recently completed Phase I/II study as adjuvant to PDT and ranibizumab [33]. Topical tyrosine kinase inhibitors currently undergoing Phase II clinical studies include pazopanib [34] and TG100801 [35]. Another approach utilizes siRNA to silence genes which express proteins involved in angiogenesis. Bevasiranib, an siRNA that targets VEGF-A mRNA, showed encouraging Phase I and II data, but the Phase III trial was halted in March 2009 for projected failure to meet the primary end point [36]. An extra antiangiogenic target being developed is pigment epithelium-derived factor (PEDF), a potent inhibitor of new vessel growth. AdGVPEDF.11D uses an adenovector to deliver the PEDF gene to target cells, resulting in the local production of PEDF in the treated eye. AdGVPEDF.11D has recently completed Phase I clinical trials [37]. Another

recently discovered alternative pathway for decreasing angiogenesis involves inhibition of nicotinic acetylcholine receptors. ATG3 (mecamylamine), a topical formulation that inhibits the nicotinic acetylcholine receptors, has shown promising results in animal and Phase I trials and is currently undergoing a Phase II study [25].

## 2.2 Introduction to compound

VEGF Trap-Eye is a novel anti-VEGF drug currently in commercial development for the treatment of neovascular AMD by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) in the US and in collaboration with Bayer HealthCare (Leverkusen, Germany) in global markets. Structurally, VEGF Trap-Eye is a fusion protein of key binding domains of human VEGFR-1 and -2 combined with a human IgG Fc fragment (Figure 1). Functionally, VEGF Trap-Eye acts as a receptor decoy with high affinity for all VEGF isoforms, binding more tightly than their native receptors. Unlike anti-VEGF drugs currently in use, VEGF Trap-Eye is designed to inhibit placental growth factors-1 and -2 in addition to all isoforms of VEGF-A.

## 2.3 Chemistry

VEGF Trap-Eye and aflibercept (the oncology product) have the same molecular structure, but there are substantial differences between the preparation of the purified drug product and their formulations. Both aflibercept and VEGF Trap-Eye are manufactured in bioreactors from industry standard Chinese hamster ovary cells that overexpress the fusion protein. However, VEGF Trap-Eye undergoes further purification steps during manufacturing to minimize risk of irritation to the eye. VEGF Trap-Eye is also formulated with different buffers and at different concentrations (for buffers in common) suitable for the comfortable, non-irritating, direct injection into the eye.

## 2.4 Pharmacodynamics

The aflibercept dose that is administered in oncology settings is either 4 mg/kg every 2 weeks or 6 mg/kg every 3 weeks, which corresponds to 2 mg/(kg week) with either schedule. The highest intravitreal dose being used in pivotal trials for VEGF Trap-Eye is 2 mg/month, which corresponds to at least a 280-fold lower potential systemic exposure than in the oncology setting. Early trials with aflibercept administered intravenously for AMD indicated that doses of 0.3 mg/kg (21 mg total) were inadequate to fully capture systemic VEGF. Thus, the low intravitreal dose of 2 mg allows for extended blocking of VEGF in the eye, but would be predicted to give negligible systemic activity as it will be rapidly bound to VEGF and inactivated.

## 2.5 Pharmacokinetics and metabolism

Aflibercept is cleared from circulation through two pathways: by binding to VEGF to form an inactive VEGF–aflibercept complex and by Fc-receptor or pinocytotic mediated pathways

that end in proteolysis, which are presumed to be similar to pathways that metabolize antibodies. At very high doses, free aflibercept has a terminal half-life of ~ 17 days in the circulation. The half-life of human intravitreal doses is unknown. Intravitreal primate doses of ranibizumab have a half-life of ~ 3 days [38]. At low blood levels, clearance of free aflibercept is rapid as a result of binding to VEGF with picomolar affinity [39].

## 2.6 Clinical efficacy

### 2.6.1 Phase I

A Phase I, randomized, double-blind, placebo-controlled trial of intravenous aflibercept (oncology formulation) was completed in 25 patients with AMD. Although systemic aflibercept did demonstrate a dose-dependent decrease in retinal thickness, the study was halted due to concerns of dose-dependent toxicity when one patient developed hypertension and another proteinuria [40].


The safety, tolerability and biological activity of intravitreal VEGF Trap-Eye in treatment of neovascular AMD was evaluated in the two-part Clinical Evaluation of Anti-angiogenesis in the Retina-1 (CLEAR-IT-1) study [41]. The first part was a sequential cohort dose-escalation study in which 21 patients were monitored for safety, changes in foveal thickness on OCT, best corrected visual acuity (BCVA) and lesion size on FA for 6 weeks. No adverse systemic or ocular events were noted and visual acuity remained stable or improved  $\geq 3$  lines in 95% of patients with a mean increase in BCVA of 4.6 letters at 6 weeks [42]. Patients showed substantially decreased foveal thickness [41].

In the second part, 30 patients received a single intravitreal injection of either 0.5 or 4 mg of VEGF Trap-Eye and were followed for 8 weeks. All patients were evaluated for their rates of retreatment, changes in BCVA, foveal thickness as well as change in total lesion size and area of CNV. Patients had ETDRS (Early Treatment of Diabetic Retinopathy Study) BCVA ranging from 20/40 to 20/320 with any angiographic subtype of CNV at baseline. No serious adverse events or ocular inflammation was identified during the study. At 8 weeks, the mean decrease in retinal thickness in the low dose group was 63.7  $\mu\text{m}$  compared to 175  $\mu\text{m}$  for the high dose group. Of the first 24 patients to complete the study, 11 out of 12 patients in the 0.5 mg dose group required retreatment in a median of 64 days, compared with 4 out of 12 in the 4 mg dose group who required retreatment in a median of 69 days [43].

VEGF Trap-Eye has also undergone a small open-label safety study for the treatment of diabetic macular edema (DME) [44]. The drug was administered as a single 4 mg intravitreal injection to five patients with longstanding diabetes and several previous treatments for DME. The single injection resulted in a median decrease of central macular thickness measured by OCT of 79  $\mu\text{m}$ . BCVA increased by 9 letters at 4 weeks and regressed to a 3 letter improvement at 6 weeks.



## VEGF Trap-Eye



**Figure 1. Schematic diagram of VEGF Trap-Eye, a fusion protein of binding domains of VEGF receptors-1 and -2 attached to the Fc fragment of human IgG.**

### 2.6.2 Phase II

CLEAR-IT-2 trial [45] was a prospective, randomized, multi-center, controlled dose- and interval-ranging Phase II trial in which 157 patients were randomized to five dose groups and treated with VEGF Trap-Eye in one eye. The mean age of the group was 78.2 years and all angiographic subtypes of CNV were represented at baseline. The mean ETDRS BCVA in letters at baseline was 56. Two groups received monthly doses of either 0.5 or 2.0 mg for 12 weeks (at weeks 0, 4, 8 and 12) and three groups received quarterly doses of either 0.5, 2.0 or 4.0 mg for 12 weeks (at weeks 0 and 12). Following this fixed dosing period, patients were treated with the same dose of VEGF Trap-Eye on a p.r.n. basis. Criteria for re-dosing included an increase in central retinal thickness of  $\geq 100 \mu\text{m}$  by OCT, a loss of  $\geq 5$  ETDRS letters in conjunction with recurrent fluid by OCT, persistent fluid as indicated by OCT, new onset classic neovascularization, new or persistent leak on FA or new macular subretinal hemorrhage.

Patients initially treated with 2.0 or 0.5 mg of VEGF Trap-Eye monthly achieved mean improvements of 9.0 ( $p < 0.0001$ ) and 5.4 ( $p < 0.085$ ) ETDRS letters with 29 and 19% gaining, respectively,  $\geq 15$  ETDRS letters at 52 weeks. During the p.r.n. dosing period, patients initially dosed on a 2.0 mg monthly schedule received an average of 1.6 more injections and those initially dosed on a 0.5 mg monthly schedule received an average of 2.5 injections. The median time to first reinjection in all groups was 110 days and 19% of patients required no more injections at week 52. Patients in these two monthly dosing groups also displayed mean decreases in

retinal thickness versus baseline of  $143 \mu\text{m}$  ( $p < 0.0001$ ) in the 2.0 mg group and  $125 \mu\text{m}$  ( $p < 0.0001$ ) in the 0.5 mg group at 52 weeks as measured by OCT [45].

Patients in the three quarterly dosing groups also showed mean improvements in BCVA and retinal thickness; however, they were generally not as profound as the monthly injection group [45].

### 2.6.3 Phase III

A two part Phase III trial of VEGF Trap-Eye was initiated in August of 2007. The first part, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) [46] will enroll  $\sim 1200$  patients with neovascular AMD in the US and Canada. This non-inferiority study will evaluate the safety and efficacy of intravitreal VEGF Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week dosing intervals and 2.0 mg at an 8 week dosing interval (following three monthly doses), compared with 0.5 mg of ranibizumab administered every 4 weeks. After the first year of the study, patients will enter a second year of p.r.n. dosing evaluation. The VIEW 2 [47] study has a similar study design and is currently enrolling patients in Europe, Asia Pacific, Japan and Latin America. In both trials, the primary outcome will be the proportion of patients who maintain vision at week 52 (defined as a loss of  $< 15$  ETDRS letters).

### 2.7 Safety and tolerability

Based on Phase II study data, VEGF Trap-Eye seems to be generally well tolerated with no serious drug-related adverse events. In the 157 patients enrolled in CLEAR-IT 2 trial, there was one reported case of culture-negative endophthalmitis not deemed to be related to the study drug. There were also two deaths (one from pre-existing pulmonary hypertension and one from pancreatic carcinoma) and one arterial thromboembolic event (in a patient with a history of previous stroke) that occurred during the study period, but no serious systemic adverse events were deemed related to VEGF Trap-Eye administration. The most common adverse events reported in the study included conjunctival hemorrhage (38.2%), transient increased intraocular pressure (18.5%), refraction disorder (15.9%), retinal hemorrhage (14.6%), subjective visual acuity loss (13.4%), vitreous detachment (11.5%) and eye pain (9.6%) [45].

### 3. Conclusion

Anti-VEGF therapy has vastly improved the treatment of neovascular AMD in terms of both safety and efficacy. The ANCHOR [26] and MARINA [27,28] trials have established ranibizumab as an effective therapy when dosed monthly. It has been shown to stabilize vision in 94% of patients and in almost 40% of patients vision will actually improve by 3 or more lines. However, the monthly dosing schedules used in these trials present a financial and time burden to patients and healthcare practitioners. The more recent PIER [30] and

PrONTO [29] trials have shown that ranibizumab is less effective when dosed quarterly, but it may be possible to extend the time between injections when patients are followed closely with frequent examinations and ancillary testing. The most effective dosing regimen and monitoring program for anti-VEGF therapy has yet to be firmly established but new treatments are aimed at extending and improving on the efficacy of ranibizumab. VEGF Trap-Eye differs from established anti-VEGF therapies in its higher binding affinity for VEGF-A and its blockage of placental growth factors-1 and -2. Phase I data demonstrated acceptable safety and tolerability of VEGF Trap-Eye in the treatment of neovascular AMD. In Phase II study data, patients dosed in a similar fashion to the PrONTO trial demonstrated stabilization of their vision that was similar to previous studies of ranibizumab at 1 year. Of the greatest interest, patients dosed at 2.0 mg during the initial monthly dosing period required 1.6 injections on average during the p.r.n. dosing phase. While this number is difficult to compare directly to the number of injections required during the p.r.n. phase of the PrONTO ranibizumab study, it is promising. A direct comparison of the efficacy of VEGF Trap-Eye versus ranibizumab will be possible with the completion of two Phase III trials, the VIEW-1 and -2 studies.

#### 4. Expert opinion

The advent of anti-VEGF therapy for treatment of neovascular AMD has revolutionized therapy for a common blinding disease. Before the development of pegaptanib, ranibizumab and bevacizumab, the diagnosis of neovascular AMD portended a prognosis of nearly universal decline in vision, and frequently loss of useful vision in the affected eye.

Current treatment regimens with either ranibizumab or bevacizumab now afford stabilization of vision in > 90% of patients, with significant vision gain in one-third of all patients treated. There have been no significant, proven adverse systemic effects with the intraocular use of either drug. However, limitations of current therapy include the need for frequent intraocular injections, as often as monthly, without a defined stopping point. Each injection subjects patients to risks of cataract, intraocular inflammation, retinal detachment and endophthalmitis. A significant time and financial burden falls on patients during their treatment course.

Desirable attributes for emerging therapies for neovascular AMD include higher visual improvement rates and decreased dosing intervals. For other indications, time-release delivery methods have met with some success, including the following agents: intraocular steroids, including polymeric fluocinolone and dexamethasone, lasting 3 years and 6 months, respectively [48-50], and for a single biologically active cytokine, ciliary neurotrophic factor, which is released for a period greater than 1 year by encapsulated, bioengineered, implanted cells [51]. While efforts are underway to develop

encapsulated cell technology for sustained-release anti-VEGF therapy, no investigational drugs or devices have progressed yet to clinical trial enrollment.

VEGF Trap-Eye represents the most promising anti-VEGF investigational drug that is currently in Phase III trial. VEGF Trap-Eye, a decoy VEGF receptor protein, binds all isoforms of free VEGF with high affinity, in addition to placental growth factor. In contrast to current anti-VEGF antibodies, which are rapidly cleared, the VEGF-VEGF Trap complex is relatively inert, and is degraded more slowly. Due to its high binding affinity and the ability to safely inject high doses into the eye, VEGF Trap-Eye may have longer duration of effect in the eye. Two Phase III studies in wet AMD, VIEW 1 and VIEW 2, are currently under way and seek to compare monthly ranibizumab to monthly or bimonthly VEGF Trap-Eye.

Data from the Phase II study with VEGF Trap-Eye were positive and the results from the non-inferiority Phase III trials will establish its efficacy versus ranibizumab. Its adoption into clinical practice will depend on efficacy at 4 and 8 week intervals. If effective at 4 week intervals only, VEGF Trap-Eye will be adopted into clinical practice if it offers a competitive price advantage over ranibizumab. If effective at 8 week intervals, VEGF Trap-Eye offers the opportunity to significantly reduce treatment burden on patients and physicians, and would probably find wide acceptance. The second p.r.n. dosing stage of the Phase III trial will also provide insight into whether VEGF Trap-Eye offers longer duration of treatment effectiveness than ranibizumab.

Data from the VIEW-1 and VIEW-2 trials will need to be interpreted by clinicians in the context of emerging adjuvant therapies that may extend the time between anti-VEGF therapy injections. Many clinicians now treat patients with anti-VEGF therapies in combination with verteporfin PDT. Randomized, open-label studies and one large retrospective case series database seem to indicate lower retreatment rates and improved visual outcomes when compared with monotherapy [52-55]. As a result, at least two prospective, randomized trials are currently underway to further examine combination verteporfin PDT and anti-VEGF treatments [56,57]. An extra combination treatment currently under study is the use of epiretinal brachytherapy with Strontium-90 combined with bevacizumab. A recently published small pilot study showed good safety and efficacy with a single application of epiretinal radiation and two bevacizumab injections after 12 months [58]. A larger, multi-center Phase III trial is underway [59].

Anti-VEGF agents are currently only approved for the treatment of exudative AMD. The multifactorial nature of DME, including non-VEGF mediated causes such as pericyte and endothelial cell damage and tractional mechanisms, has made treatment of this condition difficult using current modalities. Clinical studies are underway with anti-VEGF agents in DME and retinal vein occlusion. VEGF Trap-Eye is under Phase II investigation in DME and Phase III investigation in central retinal vein occlusion. The

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.